- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Cimzia Is Approved for Psoriatic Arthritis
Drug’s anti-inflammatory effects relieve joint pain and stiffness (September 30)
The FDA has approved UCB’s certolizumab pegol (Cimzia) for the treatment of psoriatic arthritis (PsA) in adults. This inflammatory disease affects the joints and tendons and usually occurs in combination with psoriasis.
Certolizumab pegol is a humanized, pegylated tumor necrosis factor-alpha inhibitor. It is supplied as a powder for reconstitution into a liquid formulation designed for subcutaneous administration.
PsA affects approximately 0.24% of the population worldwide. Nearly 25% of patients with psoriasis in the U.S. may have undiagnosed PsA.
In the Phase III RAPID–PsA study, the medication rapidly improved the signs and symptoms of PsA as early as the first week of treatment for some patients.
In the U.S., this medication was approved for the treatment of moderate-to-severe rheumatoid arthritis in 2009. It was originally approved in 2008 for reducing the signs and symptoms of Crohn’s disease.
The FDA is also reviewing a filing for certolizumab pegol for the treatment of adults with active axial spondyloarthritis, including patients with ankylosing spondylitis.[Source: UCB Media Centre, September 30, 2013]